The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma [0.03%]
免疫检查点调节剂对可切除肝细胞癌患者临床病程的影响
Jihyun An,Hyo Jeong Kang,Eunsil Yu et al.
Jihyun An et al.
Background/aim: Immune checkpoint proteins regulating T-cell mediated anti-tumor immunity have been reported to affect clinical outcomes in multiple malignancies. This study aimed to investigate the prognostic effect of h...
Long-term survival after CCRT and HAIC followed by ALPPS for hepatocellular carcinoma with portal vein invasion: a case report [0.03%]
肝癌伴门静脉侵犯患者接受CCRT和HAIC联合ALPPS治疗后长期存活的病例报告
In-Jung Kim,Sung Hwan Yoo,Jung Il Lee et al.
In-Jung Kim et al.
There are various methods for treating advanced hepatocellular carcinoma with portal vein invasion, such as systemic chemotherapy, transarterial chemoembolization, transarterial radioembolization, and concurrent chemoradiotherapy. These met...
Multidisciplinary treatment with immune checkpoint inhibitors for advanced stage hepatocellular carcinoma [0.03%]
多学科联合免疫检查点抑制剂治疗晚期肝细胞癌
Ahlim Lee,Jaejun Lee,Hyun Yang et al.
Ahlim Lee et al.
Hepatocellular carcinoma (HCC) is a cytotoxic chemotherapy-resistant tumor and most HCCs arise in a background of liver cirrhosis of various causes. Although the IMBrave150 trial showed remarkable advancements in the treatment of unresectab...
Recent updates on the classification of hepatoblastoma according to the International Pediatric Liver Tumors Consensus [0.03%]
国际儿童肝脏肿瘤共识协会近期更新肝母细胞瘤的分型及相关研究进展
Se Un Jeong,Hyo Jeong Kang
Se Un Jeong
Hepatoblastoma is the most common pediatric liver malignancy and usually occurs within the first 3 years of life. In recent years, the overall incidence of hepatoblastoma has exhibited the greatest increase among all pediatric malignancies ...
Radioembolization for hepatocellular carcinoma: what clinicians need to know [0.03%]
肝细胞癌的放射栓塞治疗：临床医生需要了解什么
Jin Woo Choi,Hyo-Cheol Kim
Jin Woo Choi
Transarterial radioembolization (TARE) with yttrium 90 (90Y) has been used in the management of hepatocellular carcinoma (HCC) for more than 10 years in Korea. There are two types of 90Y radioactive microspheres available, namely, glass and...
A case report of advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy and sorafenib combination therapy followed by metastasectomy of lung and muscle metastases [0.03%]
肝动脉灌注化疗联合索拉非尼治疗晚期肝细胞癌合并肺肌转移的手术切除病例报告
Sang Yi Moon,Sang Young Han,Yang-Hyun Baek
Sang Yi Moon
Currently, various tyrosine kinase inhibitors and immune checkpoint inhibitors have been suggested in the treatment guidelines for advanced hepatocellular carcinoma (HCC). However, sorafenib was the only systemic drug approved 10 years ago....
Diagnostic performance of serum exosomal miRNA-720 in hepatocellular carcinoma [0.03%]
血清外泌体miRNA-720诊断肝细胞癌的性能评估
Jeong Won Jang,Ji Min Kim,Hye Seon Kim et al.
Jeong Won Jang et al.
Background/aim: Hepatocellular carcinoma (HCC) is associated with poor prognosis, largely due to late detection. Highly accurate biomarkers are urgently needed to detect early-stage HCC. Our study aims to explore the diag...
Salvatore Lorenzo Renne,Luca Di Tommaso
Salvatore Lorenzo Renne
It is estimated that more than 1 million individuals will be affected annually by hepatocellular carcinoma (HCC) by 2025. HCC can be broadly grouped into two major molecular subgroups, each of which is characterized by specific morphologica...
Is multidisciplinary treatment effective for hepatocellular carcinoma with portal vein tumor thrombus? [0.03%]
多学科治疗对门静脉瘤栓肝细胞癌有效吗？
Won Hyeok Choe
Won Hyeok Choe
Fibrolamellar hepatocellular carcinoma that was successfully treated with surgical resection: a case report [0.03%]
一例成功通过手术切除治疗的纤维板层型肝细胞癌病例报告
Seong Kyun Na
Seong Kyun Na
Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare malignant hepatic cancer with characteristics that differ from those of typical hepatocellular carcinoma (HCC). Unlike conventional HCC, FLHCC is common in young patients without any ...